Jkj, just following up again on your excellent post which IMHO bodes extremely well for rvx-208.

The last line which is a conclusion is very intriguing. It reads as follows;

"The results point to the growing body of evidence revealing that drugs capable of effectively lowering glucose levels in patients with diabetes 'do not' seem to be capable of lowering CVD risks."

Therefore, why does rvx-208 dramatically lower MACE/CVD in patients with diabetes mellitus and CVD with a RRR (relative risk reduction) of 77% (p=0.02) (ASSURE/SUSTAIN) and an absolute risk reduction of approximately 16% points = (21% - 6%)? What is the method by which rvx-208 dramatically reduces cardiovascular risk? And why does rvx-208 achieve a RRR of 55%(p=0.01) MACE reduction within the total sample? And rvx-208 achieved these results in 210 days of dosing and the dosing effects became evident at the first measurement period which was at 15 days. I think it is remarkable!

What we do know with almost absolute certainty (p<0.001) is that rvx-208 increases ApoA-l which means it increases "functional" HDL (good cholesterol) as pointed out by BearDownAZ. There was also evidence recently published about the rvx-208 impact on glucose but that requires a science poster to comment on.

I sure would like to hear from science posters regarding the study posted by Jkj and the conclusion above. I think this bodes extremely well for rvx-208.

Cheers

Toinv :)